NoHarm.ai

What NoHarm.ai does

NoHarm.ai is a Brazilian nonprofit SaaS platform that applies AI to hospital clinical pharmacy, operating under the legal entity Instituto de Inteligência Artificial na Saúde. The system integrates with hospital Electronic Health Record (EHR) platforms including MV, Tasy, TOTVS, Salux, and AGHU, processing prescription data, lab results, and clinical notes to surface out-of-standard prescriptions, drug interactions, altered lab exams, and patient risk stratification in real time. Its portfolio comprises a core prescription-validation engine, the NoHarm Care NLP module that extracts structured indicators from clinical evolution notes, and NoHarm Navegação, a post-discharge patient navigation service.

The business model uses tiered monthly subscriptions priced per private bed (R$45-R$55/bed/month) or per private patient (R$6-R$16/patient/month), plus one-time integration fees ranging from R$10,000 to R$30,000, with a R$4,000 monthly minimum. Under a cross-subsidy structure, 100% SUS (Brazilian public healthcare) institutions receive the platform free of charge, funded by private hospital subscriptions. Distribution is direct enterprise sales to hospitals, with additional reach through philanthropic networks (Federassantas) and public initiatives like Juntos pela Saúde.

The platform reports 150+ healthcare units in production, 90 million prescriptions evaluated, 1.2 million lives impacted, and R$30 million in cumulative customer savings. Documented 2024 operational revenue of the Instituto entity was R$6.88M. Strategic backing includes BNDES, the Bill & Melinda Gates Foundation, Umane, and CNPq, with technology partners AWS, Google for Nonprofits, Oracle for Startups, NVIDIA, and META.

Name

NoHarm.ai

Legal name

Instituto de Inteligência Artificial na Saúde

Website

https://noharm.ai

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

NoHarm.ai is a Brazilian AI-powered SaaS platform that integrates with hospital EHR systems to automate clinical pharmacy decision support, prioritizing out-of-standard prescriptions and identifying patient risks. It serves 150+ hospitals and ambulatory care providers, charging private institutions on a tiered per-bed subscription while providing the platform free to SUS public healthcare facilities.

Ownership category

akta.pro rank

Product category

Clinical Pharmacy Software

NAICS

Software Publishers (513210)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

EHR/EMR Integration & Interoperability Middleware (HL7/FHIR) (HLALAKAD)

Keywords

• Clinical pharmacy software
• AI prescription validation
• Hospital pharmacy automation
• EHR-integrated pharmacy
• Medication safety platform

Headquarters

HQ city

Porto Alegre, RS

HQ country

Serbia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Hospital Bed Subscription (Private): Monthly subscription fees based on number of private beds. Tiers: up to 200 beds at R$55/bed/month, up to 500 beds at R$50/bed/month, 500+ beds at R$45/bed/month. Minimum contract value of R$4,000 for private beds/patients.
2. Patient Subscription (Private): Monthly per-patient fees for outpatient/ambulatory care. Tiers: up to 200 patients at R$16/patient/month, up to 500 patients at R$11/patient/month, 500+ patients at R$6/patient/month.
3. Implementation/Integration Services: One-time integration fees: R$30,000 for up to 200 beds, R$20,000 for up to 500 beds, R$10,000 for 500+ beds. VPN site-to-site incurs additional project costs.
4. Public Healthcare (SUS): Free service for SUS (public healthcare system) beds, validated through CNES (National Registry of Health Establishments). For 100% SUS institutions, service is free with collaboration agreements without financial burden.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels8 records

Core offering

NoHarm.ai provides a SaaS platform that uses artificial intelligence and natural language processing to support clinical pharmacy activities in hospitals. The platform automates prescription validation and clinical text analysis for pharmacists, integrates with hospital electronic health record systems, and is offered free to public SUS hospitals and through paid subscriptions to private hospitals.

Product overview

NoHarm.ai is a SaaS platform for hospital clinical pharmacy that offers AI-assisted prescription evaluation and pharmaceutical screening. The portfolio consists of the core NoHarm.ai platform plus two add-on modules: NoHarm Care (NLP-powered clinical text analysis) and NoHarm - Navegação (post-discharge patient navigation service). The platform integrates with hospital EHR systems (MV, Tasy, TOTVS, Salux, AGHU), processes prescription and lab data through algorithms developed with Porto Alegre hospitals, and is offered free of charge to SUS (Brazil's public health system) while private/insurance beds are billed per bed per month. An associated nonprofit entity, the Instituto de I.A. na Saúde, develops open-knowledge AI technology for healthcare improvement.

Differentiator

Problem solved

Functional benefit

Brands

• NoHarm Care: AI feature that classifies and annotates patient indicators in clinical progress notes, extracting relevant information and enabling exam analysis and risk management report generation.

Products and services

• NoHarm.ai Platform SaaS platform that uses AI and natural language processing to automate prescription validation and clinical pharmacy review for hospital pharmacy departments and pharmacists.
• NoHarm - Navegação Post-discharge patient navigation service that supports continuity of care for patients leaving the hospital, intended for hospital and care coordination teams.

Quantifiable outcome

• R$ 672,000 in savings with 95% intervention acceptance rate at Hospital São Vicente de Paulo in 6 months
• +3 more outcomes

Named customers34 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability5 records

Feature7 records

Partnerships

One partnership is on record.

• Tecnopuc - Parque TecnológicocoreStrategic or Co-development PartnerTechnology park associated with PUCRS university in Porto Alegre, providing innovation ecosystem support and potentially facilitating hospital partnerships for algorithm development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• DoseMeRx: DoseMeRx provides AI-enabled precision dosing decision support for hospitals, particularly for vancomycin and aminoglycosides. While narrower than NoHarm's full prescription-evaluation scope, it represents a comparable AI-driven clinical pharmacy SaaS model targeting hospital integration.
• Arrive Health (formerly RxRevu): Arrive Health provides prescription decision support at the point of prescribing, surfacing cost, coverage, and clinical appropriateness information to clinicians. Comparable to NoHarm in applying real-time analytics to prescription data, though focused on prescribing workflows rather than inpatient pharmacy surveillance.
• First Databank (FDB): FDB provides drug knowledge bases and clinical decision support (CDS) tools integrated into hospital EHRs for medication safety, interaction screening, and dosing alerts. Directly comparable to NoHarm.ai as a clinical pharmacy decision support vendor relying on curated drug knowledge and integration with hospital data systems.
• Tabula Rasa HealthCare (MedWise): Tabula Rasa's MedWise platform uses pharmacogenomics and multi-drug interaction analysis to identify medication safety risks, directly competing with NoHarm's patient risk stratification and drug interaction detection capabilities for hospital and ambulatory pharmacy customers.
• Wolters Kluwer Sentri7: Wolters Kluwer's Sentri7 is a clinical surveillance platform used by hospital pharmacies for real-time alerting on drug interactions, dosing errors, and patient risk stratification. Directly comparable to NoHarm.ai's core value proposition of AI-powered prescription evaluation and clinical pharmacy decision support.

Regional players

• Pixeon: Pixeon is a Brazilian health-IT vendor offering hospital management software, RIS/PACS, and LIS solutions. Regional player with comparable Brazilian healthcare customer base, though not directly competing in clinical pharmacy decision support; representative of local incumbent health-IT vendors NoHarm must partner with or differentiate against.

Broad incumbents

• Omnicell: Omnicell offers a broad portfolio of medication management solutions for hospitals including pharmacy automation, IV compounding, and clinical decision support. Overlaps with NoHarm's hospital pharmacy workflow optimisation but operates at a much larger scale across multiple solution categories.
• Becton Dickinson (BD) Pharmacy Solutions: BD's medication management portfolio includes Pyxis dispensing systems and clinical surveillance capabilities for hospital pharmacies. Competes with NoHarm in the hospital pharmacy workflow and medication safety category, though BD's primary strength is in dispensing hardware rather than AI decision support.
• Epic Systems (Pharmacy Module): Epic's EHR includes built-in pharmacy decision support, drug-interaction alerts, and dosing guidance that compete directly with NoHarm's value proposition. As hospitals standardise on Epic-like EHRs, native pharmacy features may reduce the need for third-party decision-support platforms like NoHarm.
• Elsevier Clinical Solutions (ClinicalPath): Elsevier offers evidence-based clinical decision support tools across care pathways, with pharmacy and medication safety components. Broad incumbent competing for hospital pharmacy budget alongside dedicated vendors like NoHarm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/noharm-ai

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NoHarm.ai